Kardiyovasküler Hastalıklarda Matriks Metalloproteinazların Önemi
Özet
Kardiyovasküler hastalıklar (KVH), dünya genelinde kronik hastalıklar ve ölüm nedenleri arasında ilk sırada yer almaktadır. Bu hastalıkların gelişiminde ve doku onarım süreçlerinde, hücre dışı matriksin (ECM) yıkımından sorumlu olan matriks metalloproteinaz (MMP) enzim ailesi kritik bir rol oynamaktadır. MMP'ler; doku yeniden şekillenmesi, anjiyogenez ve enflamasyon gibi fizyolojik süreçlerin yanı sıra ateroskleroz, miyokardiyal infarktüs (MI), abdominal aort anevrizması ve hipertansiyon gibi patolojik durumlarda da aktif görev alırlar. Aterosklerozda MMP'ler, plak stabilitesini bozarak yırtılmalara ve akut koroner sendromlara yol açabilmektedir. MI sonrası süreçte ise bu enzimlerin artan aktivitesi, ventriküler yeniden şekillenme ve kalp yetmezliği riskini beraberinde getirmektedir. Ayrıca, hipertansiyon ve preeklampsi gibi durumlarda damar duvarının yapısal değişimine katkıda bulunurlar. MMP aktiviteleri, gen ekspresyonu ve doku inhibitörleri (TIMP'ler) tarafından titizlikle dengelenmektedir. Bu enzimlerin rollerinin tam olarak aydınlatılması, KVH'lerin erken teşhisinde biyobelirteç olarak kullanılmalarına ve yeni tedavi stratejilerinin geliştirilmesine olanak tanıyacaktır.
Cardiovascular diseases (CVD) rank first among chronic diseases and causes of death worldwide. The matrix metalloproteinase (MMP) enzyme family, responsible for the degradation of the extracellular matrix (ECM), plays a critical role in the development and tissue repair processes of these diseases. MMPs take an active part in physiological processes such as tissue remodeling, angiogenesis, and inflammation, as well as pathological conditions including atherosclerosis, myocardial infarction (MI), abdominal aortic aneurysm, and hypertension. In atherosclerosis, MMPs can lead to plaque instability, resulting in ruptures and acute coronary syndromes. In the post-MI period, the increased activity of these enzymes brings risks of ventricular remodeling and heart failure. Additionally, they contribute to the structural transformation of the vessel wall in conditions like hypertension and preeclampsia. MMP activities are meticulously balanced by gene expression and tissue inhibitors (TIMPs). Fully elucidating the roles of these enzymes will enable their use as biomarkers for early diagnosis of CVD and the development of new therapeutic strategies.
Referanslar
Yeşil P, Altınok M. Kardiyovasküler hastalıkların önlenmesi ve kontrolünde fiziksel aktivitenin önemi. Türk Kardiyoloji Derneği Kardiyovasküler Hemşirelik Dergisi, 2012; 1-10. doi:10.5543/khd.2012.005
Creemers EE, Cleutjens JP, Smits JF, et al. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?. Circ Res. 2001;89(3): 201-210. doi:10.1161/hh1501.094396. PMID: 11485970.
Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res. 2003;59(4): 812-823. doi:10.1016/s0008-6363(03)00516-9. PMID: 14553821.
Diehm C, Lange S, Darius H, et al. Association of low ankle brachial index with high mortality in primary care. Eur Heart J. 2006;27(14):1743-1749. doi:10.1093/eurheartj/ehl092. PMID: 16782720.
Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020;76(25): 2982-3021. doi:10.1016/j.jacc.2020.11.010. PMID: 33309175.
Rundhaug JE. Matrix metalloproteinases and angiogenesis. J Cell Mol Med. 2005;9(2): 267-285. doi:10.1111/j.1582-4934.2005.tb00355.x. PMID: 15963249.
Wiseman BS, Sternlicht MD, Lund LR, et al. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J Cell Biol. 2003;162(6): 1123-1133. doi:10.1083/jcb.200302090. PMID: 12975354.
Foidart P, Yip C, Radermacher J, et al. Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. Clin Cancer Res. 2019;25(6): 1838-1850. doi:10.1158/1078-0432.CCR-18-1880. PMID: 30504427.
Garcia-Fernandez N, Jacobs-Cachá C, Mora-Gutiérrez JM, et al. Matrix Metalloproteinases in Diabetic Kidney Disease. J Clin Med. 2020;9(2): 472. doi:10.3390/jcm9020472. PMID: 32046355.
Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31): 21491-21494. doi:10.1074/jbc.274.31.21491. PMID: 10419448.
Lee MH, Murphy G. Matrix metalloproteinases at a glance. J Cell Sci. 2004;117(18): 4015-4016. doi:10.1242/jcs.01223. PMID: 15316076.
McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore!. Curr Opin Cell Biol. 2001;13(5): 534-540. doi:10.1016/s0955-0674(00)00248-9. PMID: 11544020.
Allan JA, Docherty AJ, Barker PJ, et al. Binding of gelatinases A and B to type-I collagen and other matrix components. Biochem J. 1995;309 (1): 299-306. doi:10.1042/bj3090299. PMID: 7619071.
Sela-Passwell N, Rosenblum G, Shoham T, et al. Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?. Biochim Biophys Acta. 2010;1803(1): 29-38. doi:10.1016/j.bbamcr.2009.04.010. PMID: 19406173.
Chakraborti S, Mandal M, Das S, et al. Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem. 2003;253(1-2): 269-285. doi:10.1023/a:1026028303196. PMID: 14619979.
Phatharajaree W, Phrommintikul A, Chattipakorn N. Matrix metalloproteinases and myocardial infarction. Can J Cardiol. 2007;23(9): 727-733. doi:10.1016/s0828-282x(07)70818-8. PMID: 17622396.
Heagerty AM, Aalkjaer C, Bund SJ, et al. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension.1993;21(4):391-397. doi:10.1161/01.hyp.21.4.391. PMID: 8458640.
Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008;75(2): 346-359. doi:10.1016/j.bcp.2007.07.004. PMID: 17678629.
Rader DJ, Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature. 2008;451(7181): 904-913. doi:10.1038/nature06796. PMID: 18288179.
Stephen SL, Freestone K, Dunn S, et al. Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. IntJ Hypertens. 2010;2010: 646929. doi:10.4061/2010/646929. PMID: 20981357.
Olejarz W, Łacheta D, Głuszko A, et al. RAGE and TLRs as Key Targets for Antiatherosclerotic Therapy. Biomed Res Int. 2018;2018: 7675286. doi:10.1155/2018/7675286. PMID: 30225265.
Olejarz W, Głuszko A, Cyran A, et al. TLRs and RAGE are elevated in carotid plaques from patients with moderate-to-severe obstructive sleep apnea syndrome. Sleep Breath. 2020;24(4): 1573-1580. doi:10.1007/s11325-020-02029-w. PMID: 32076951.
Myasoedova VA, Chistiakov DA, Grechko AV, et al. Matrix metalloproteinases in pro-atherosclerotic arterial remodeling. J. Mol. Cell. Cardiol. 2018;123: 159-167. doi:10.1016/j.yjmcc.2018.08.026. PMID: 30172754.
Brown BA, Williams H, George SJ. Evidence for the Involvement of Matrix-Degrading Metalloproteinases (MMPs) in Atherosclerosis. Prog Mol Biol Transl Sci. 2017;147: 197-237. doi:10.1016/bs.pmbts.2017.01.004. PMID: 28413029.
Wang X, Khalil RA. Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease. Adv Pharmacol. 2018;81: 241-330. doi:10.1016/bs.apha.2017.08.002. PMID: 29310800.
Purroy A, Roncal C, Orbe J, et al. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification. Atherosclerosis. 2018;278: 124-134. doi:10.1016/j.atherosclerosis.2018.09.022. PMID: 30268068.
Hernandez-Anzaldo S, Brglez V, Hemmeryckx B, et al. Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism. J Am Heart Assoc. 2016;5(10): e004228. doi:10.1161/JAHA.116.004228. PMID: 27694328.
Inokubo Y, Hanada H, Ishizaka H, et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J. 2001;141(2): 211-217. doi:10.1067/mhj.2001.112238. PMID: 11174334.
Zaltsman AB, Newby AC. Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: relationship to lesion severity. Atherosclerosis. 1997;130(1-2): 61-70. doi:10.1016/s0021-9150(96)06046-7. PMID: 9126649.
Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol. 1996;16(1): 28-33. doi:10.1161/01.atv.16.1.28. PMID: 8548422.
Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90(3): 251-262. PMID: 11861412.
Fernandez-Patron C, Kassiri Z, Leung D. Modulation of Systemic Metabolism by MMP-2: From MMP-2 Deficiency in Mice to MMP-2 Deficiency in Patients. Compr Physiol. 2016;6(4): 1935-1949. doi:10.1002/cphy.c160010. PMID: 27783864.
Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc. Natl. Acad. Sci. U.S.A. 1996;93(18): 9748-9753. doi:10.1073/pnas.93.18.9748. PMID: 8790402.
Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation. 2001;104(16): 1899-1904. doi:10.1161/hc4101.097419. PMID: 11602491.
Cho A, Graves J, Reidy MA. Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20(12): 2527-2532. doi:10.1161/01.atv.20.12.2527. PMID: 11116048.
Olejarz W, Łacheta D, Kubiak-Tomaszewska G. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability. IntJMol Sci. 2020;21(11): 3946. doi:10.3390/ijms21113946. PMID: 32486345; PMCID: PMC7313469.
Reel B. Matriks metalloproteinaz enzimleri ve ateroskleroz. Turkiye Klinikleri J Med Sci, 2006; 26(5): 527-37.
Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J. Am. Coll. Cardiol. 2007;50(22): 2173-2195. doi:10.1016/j.jacc.2007.09.011. PMID: 18036459.
Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res. 2006;69(3): 636-645. doi:10.1016/j.cardiores.2005.07.015. PMID: 16122719.
Frangogiannis NG. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circ Res. 2019;125(1): 117-146. doi:10.1161/Cırcresaha.119.311148. PMID: 31219741.
Carlyle WC, Jacobson AW, Judd DL, et al. Delayed reperfusion alters matrix metalloproteinase activity and fibronectin mRNA expression in the infarct zone of the ligated rat heart. J. Mol. Cell. Cardiol. 1997;29(9): 2451-2463. doi:10.1006/jmcc.1997.0482. PMID: 9299368.
Cleutjens JP, Kandala JC, Guarda E, et al. Regulation of collagen degradation in the rat myocardium after infarction. J. Mol. Cell. Cardiol. 1995;27(6): 1281-1292.doi:10.1016/s0022-2828(05)82390-9. PMID: 8531210.
Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J. Mol. Cell. Cardiol. 1998;30(7): 1431-1442. doi:10.1006/jmcc.1998.0711. PMID: 9710810.
Sato S, Ashraf M, Millard RW, et al. Connective tissue changes in early ischemia of porcine myocardium: an ultrastructural study. J. Mol. Cell. Cardiol. 1983;15(4): 261-275. doi:10.1016/0022-2828(83)90281-x. PMID: 6876183.
Tyagi SC, Kumar SG, Haas SJ, et al. Post-transcriptional regulation of extracellular matrix metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell. Cardiol.1996;28(7): 1415-1428. doi:10.1006/jmcc.1996.0132. PMID: 8841929.
Bergman MR, Teerlink JR, Mahimkar R, et al. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007;292(4): 1847-1860. doi:10.1152/ajpheart.00434.2006. PMID: 17158653.
Wang GY, Bergman MR, Nguyen AP, et al. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. CardiovascRes. 2006;69(3): 688-696. doi:10.1016/j.cardiores.2005.08.023. PMID: 16183043.
Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation. 2002;106(12): 1543-1549. doi:10.1161/01.cir.0000028818.33488.7b. PMID: 12234962.
Ali MA, Chow AK, Kandasamy AD, et al. Mechanisms of cytosolic targeting of matrix metalloproteinase-2. J Cell Physiol. 2012;227(10): 3397-3404. doi:10.1002/jcp.24040. PMID: 22212960.
Ali MA, Cho WJ, Hudson B, et al. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury. Circulation. 2010;122(20): 2039-2047. doi:10.1161/Cırculatıonaha.109.930222. PMID: 21041693.
Barhoumi T, Fraulob-Aquino JC, Mian MOR, et al. Matrix metalloproteinase-2 knockout prevents angiotensin II-induced vascular injury. Cardiovasc Res.2017;113(14): 1753-1762. doi:10.1093/cvr/cvx115. PMID: 29016715.
Lalu MM, Pasini E, Schulze CJ, et al. Ischaemia-reperfusion injury activates matrix metalloproteinases in the human heart. Eur Heart J. 2005;26(1): 27-35. doi:10.1093/eurheartj/ehi007. PMID: 15615796.
Mishra A, Srivastava A, Mittal T, et al. Association of matrix metalloproteinases (MMP2, MMP7 and MMP9) genetic variants with left ventricular dysfunction in coronary artery disease patients. Clin. Chim. Acta. 2012;413(19-20): 1668-1674. doi:10.1016/j.cca.2012.05.012. PMID: 22664146.
Provenzano M, Andreucci M, Garofalo C, et al. The Association of Matrix Metalloproteinases with Chronic Kidney Disease and Peripheral Vascular Disease: A Light at the End of the Tunnel?. Biomolecules. 2020;10(1): 154. doi:10.3390/biom10010154. PMID: 31963569.
Boyle JR, McDermott E, Crowther M, et al. Doxycycline inhibits elastin degradation and reduces metalloproteinase activity in a model of aneurysmal disease. J. Vasc. Surg. 1998;27(2): 354-361. doi:10.1016/s0741-5214(98)70367-2. PMID: 9510291.
Newman KM, Malon AM, Shin RD, et al. Matrix metalloproteinases in abdominal aortic aneurysm: characterization, purification, and their possible sources. Connect Tissue Res. 1994;30(4): 265-276. doi:10.3109/03008209409015042. PMID: 7956205.
Sakalihasan N, Delvenne P, Nusgens BV, et al. Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms. J. Vasc. Surg. 1996;24(1): 127-133. doi:10.1016/s0741-5214(96)70153-2. PMID: 8691515.
Petersen E, Gineitis A, Wågberg F, et al. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg. 2000;20(5): 457-461. doi:10.1053/ejvs.2000.1211. PMID: 11112465.
Chew DK, Conte MS, Khalil RA. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J. Vasc. Surg. 2004;40(5): 1001-1010. doi:10.1016/j.jvs.2004.08.035. PMID: 15557917.
Folkman J. Angiogenesis. Annu. Rev. Med. 2006;57: 1-18. doi:10.1146/annurev.med.57.121304.131306. PMID: 16409133.
Pepper MS. Extracellular proteolysis and angiogenesis. Thromb Haemost. 2001;86(1): 346-355. PMID: 11487024.
Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8(3): 221-233. doi:10.1038/nrm2125. PMID: 17318226.
Mishra PK, Givvimani S, Chavali V, et al. Cardiac matrix: a clue for future therapy. Biochim Biophys Acta. 2013;1832(12): 2271-2276. doi:10.1016/j.bbadis.2013.09.004. PMID: 24055000.
Dülek H, Tuzcular Vural E. Z, Gönenç I. Kardiyovasküler Hastalıklarda Risk Faktörleri. Jour Turk Fam Phy. 2018; 9(2), 53-58. doi: 10.15511/tjtfp.18.00253.
Derosa G, D'Angelo A, Ciccarelli L, et al. Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium. 2006;13(3): 227-231. doi:10.1080/10623320600780942. PMID: 16840178.
Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens. 2003;17(2): 119-124. doi:10.1038/sj.jhh.1001518. PMID: 12574790.
Flamant M, Placier S, Dubroca C, et al. Role of matrix metalloproteinases in early hypertensive vascular remodeling. Hypertension. 2007;50(1): 212-218. doi:10.1161/Hypertensıonaha.107.089631. PMID: 17515450.
Merchant SJ, Davidge ST. The role of matrix metalloproteinases in vascular function: implications for normal pregnancy and pre-eclampsia. BJOG. 2004;111(9): 931-939. doi:10.1111/j.1471-0528.2004.00223.x. PMID: 15327607.
Pustovrh MC, Jawerbaum A, Capobianco E, et al. Increased matrix metalloproteinases 2 and 9 in placenta of diabetic rats at midgestation. Placenta. 2005;26(4): 339-348. doi:10.1016/j.placenta.2004.06.011. PMID: 15823620.
Galewska Z, Bańkowski E, Romanowicz L, et al. Pre-eclampsia (EPH-gestosis)-induced decrease of MMP-s content in the umbilical cord artery. Clin Chim Acta. 2003;335(1-2): 109-115. doi:10.1016/s0009-8981(03)00296-1. PMID: 12927692.
Gallery ED, Campbell S, Arkell J, et al. Preeclamptic decidual microvascular endothelial cells express lower levels of matrix metalloproteinase-1 than normals. Microvasc Res. 1999;57(3): 340-346. doi:10.1006/mvre.1998.2142. PMID: 10329260.
